A Open-Label Phase 3, Multi-Center, Parallel Group Study to evaluate Efficacy and Safety Study of GK664S in Subjects with moderate-to-severe scalp Eczema Dermatitis except for seborrheic dermatitis
Latest Information Update: 10 Jan 2022
At a glance
- Drugs GK 664S (Primary)
- Indications Eczema
- Focus Registrational; Therapeutic Use
- Sponsors Maruho
Most Recent Events
- 24 Nov 2021 Status changed from not yet recruiting to completed.
- 17 Dec 2018 New trial record